Patents
NOVAiCOS’ innovation is protected by a solid patent strategy, ensuring
exclusivity and competitiveness in the field of immunotherapy for bone
metastases.
NOVAiCOS holds two key patents, covering both osteoporosis therapy and
cancer treatment:
NOVEL ANTI-TUMOR THERAPEUTIC AGENTS Patent status: Granted in Italy (IT) and the United States (US), pending approval in Canada (CA) and Europe (EP)
Discover more
LIGANDS OF THE B7H RECEPTOR FOR THE TREATMENT OF OSTEOPENIA AND OSTEOPOROSIS. Patent status: Granted in China (CN), Canada (CA), United States (US), and Europe (EP)
Discover more
NOVEL ANTI-TUMOR THERAPEUTIC AGENTS
The active ingredient ICOS-Fc
encapsulated in biocompatible
nanoparticles has proven effective as an
anti-tumor agent.
This ICOS-Fc
formulation inhibits tumor growth and
metastatization by inhibiting the
formation of new vessels and
modulating the immune response
against the tumor.
The action of ICOS-Fc
is independent of the type of tumor and
the nanoparticles in which it is
encapsulated.
Technical features
The patent describes the use ICOS-Fc encapsulated in biodegradable and biocompatible nanoparticles in the treatment of neoplastic growth. In the transplantable B16 melanoma tumor model, ICOS- Fc encapsulated in b-cyclodextrin nanosponges shows a powerful antitumor activity by inhibiting primary tumor growth, tumor metastatization, tumor neoangiogenesis and tumor-mediated immunosuppression. The effect does not depend on the type of nanoparticles and the type of tumor since a similar antitumor effect was detected using human ICOS-Fc loaded in poly (lactic-co-glycolic acid) (PLGA) nanoparticles in the same melanoma model or in a xenogenic model of glioblastoma. Taken together, these results indicate that ICOS-Fc has the potential to become a new tool for cancer therapies thanks to its multi-pronged anti-tumor activity, targeting essential stages of tumor growth.
Possible applications
- Inhibition of tumor growth and neo- angiogenesis
- Inhibition of tumor metastatization
- Bone metastasis
- In oncology field
Advantages
- Absence of cytotoxicity at the tested concentrations
- High tolerability and good stability in mice in vivo
- Ability to reduce neoplastic growth in several tumor models in mice
- Multi-level anti-tumor activity effective on tumor cells, tumor microenvironment, and anti-tumor immune response
LIGANDS OF THE B7H RECEPTOR FOR THE TREATMENT OF OSTEOPENIA AND OSTEOPOROSIS
ICOS-FC inhibits osteoclast osteolytic activity in vitro and osteoporosis in vivo.
